drugset / Trial / NCT07152769
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, controlled, open-label, single center clinical study. This study is designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Combined With GC versus Sintilimab Combined With GC as first-line therapy in advanced ICC.
Timeline
- Start
- 2025-10-15
- Primary completion
- 2028-02-29
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Comparator | Sintilimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | — |